Farallon Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$60.9M Buy
3,974,000
+1,476,000
+59% +$27.2M 0.26% 42
2026
Q2
$46.2M Buy
2,498,000
+1,582,000
+173% +$25M 0.2% 44
2026
Q1
$13.7M Buy
+916,000
New +$14.3M 0.07% 65

Other funds holding AVTX

Farallon Capital Management's AVTX Position: Q3 2026 in Review

Farallon Capital Management increased its Avalo Therapeutics (AVTX) stake by 59% in Q3 2026, buying an estimated $27.2M and bringing the position to 3,974,000 shares worth $60.9M. The position accounts for 0.26% of the portfolio, ranked #42.

Farallon Capital Management first reported a position in AVTX in Q1 2026 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Farallon Capital Management held 3,974,000 shares of Avalo Therapeutics worth $60.9M as of Q3 2026.
  • Farallon Capital Management bought 1,476,000 Avalo Therapeutics shares in Q3 2026, an estimated $27.2M.
  • Avalo Therapeutics made up 0.26% of Farallon Capital Management's portfolio in Q3 2026, its #42 holding.
  • Farallon Capital Management first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Farallon Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.